Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.
November 26, 2025 | Intelligent Commercialisation, artificial intelligence
Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.
As health and life sciences companies prepare for launch, teams often face the same challenge: data lives in silos. Omnichannel engagement data, field insights, and clinical indicators sit in separate systems – making it difficult to form a connected view of readiness or identify the levers that will most influence launch success.
InConcert™ unites these fragmented datasets to help commercial and medical leaders answer the questions that matter most:
- Which HCPs are showing early interest or unmet need?
- Where are we under- or over-investing across channels?
- How is our field and MSL activity likely to impact uptake?
- What indicators point to the strongest early launch opportunities?
By combining proprietary and client-owned data into one intelligent suite, InConcert™ transforms uncertainty into foresight – helping teams model scenarios, anticipate challenges, and activate strategies with clarity and confidence.
The full picture of commercial performance
InConcert™ integrates omnichannel, field, and clinical behavior data through an LLM-powered interface that enables intuitive, natural-language querying.
Guided by embedded data scientists and cross-functional experts from across Inizio, users can interrogate their data in real time – moving seamlessly from insight to action.
“InConcert™ helps clients bring their data into focus – turning scattered signals into a clear view of launch readiness,” said Mary-Kate McGarry, Chief Strategy & Innovation Officer, Inizio.
“When teams can see where physicians are most responsive, how field activity drives uptake, and where investment will have the greatest impact, they can make every launch decision with greater insight and confidence.”
A connected intelligence solution built for the pivotal pre-launch moment
At this stage of the lifecycle, success depends on understanding how behavior, communication, and clinical context intersect. InConcert™ combines four core data layers that, together, provide an unparalleled pre-launch vantage point:
- Omnichannel intelligence: More than 25M hours of HCP engagement data reveal where interest is building, which messages resonate, and which needs remain unmet.
- Field performance insight: Over 200 brand meeting analyses uncover how in-field activity shapes perception and influence, informing targeting and deployment strategy.
- Clinical foresight: U.S. and EU modeling of real-world evidence connects clinical signals to commercial outcomes – helping teams understand where market readiness is strongest.
- Predictive engagement: AI-driven models trained on longitudinal datasets forecast behavioral shifts, guiding investment toward the highest-impact channels and content.
Together, these layers create a continuously learning system – one that adapts to each therapy area and market, giving teams a real-time view of where and how to act.
Leading the future of Intelligent Commercialization™ with InConcert™
By uniting three critical assets, InConcert™ positions Inizio at the forefront of Intelligent Commercialization™.
- Proprietary data and infrastructure: Decades of integrated datasets spanning engagement, scientific, and commercial domains.
- A connective AI backbone: A modular, LLM-powered platform that makes complex data easy to query, interpret, and operationalize.
- Embedded expertise: Access to specialists from across Inizio – whose insights are both built into the models and available on demand – ensuring every interpretation is grounded in scientific and strategic rigor.
Fast to activate and easy to scale, InConcert™ can be deployed within 10–14 weeks, with flexible pilot options that integrate quickly into existing systems and launch workflows.
“Every InConcert™ deployment starts with a client challenge,” said Jamie Avallone, Chief Data Officer, Inizio Evoke.
“Whether it’s identifying high-value targets or validating go-to-market assumptions, InConcert™ gives teams the answers they need – turning complex data into clear, confident launch decisions.”
With more than 700 pharma and biotech partnerships, Inizio helps clients unlock the full potential of their data – transforming fragmented insights into the connected intelligence that drives confident, high-impact launches.
Learn more about InConcert™ or get in touch with one of our experts today.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Article: Market access in Brazil
All eyes on Spinraza
China: How to strategise and win in the world’s fastest changing healthcare market
In this paper, experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch...
Infographic: Preparing to launch a new asset and in need of demand assessment research?
Download our pre-launch checklist
Article: Engaging patient advocacy groups
The key to conducting effective rare disease research
Webcast: Harnessing the power of social: How to generate fresh insights for your business using social media listening
Download our third Innovation in #MRX webcast, hosted in partnership with Convosphere, where we discuss how to use social media listening to answer key business questions.Watch here: https://bit.ly/2nM0xvj
Article: Like, Like, Like: Harnessing the power of social media insights
Given the colossal amount of personal and professional information that we share online, social media channels such as Facebook and Twitter are fast becoming treasure troves of big data. As...
Infographic: China: How to keep up and win in the world’s fastest changing healthcare market
Our latest infographic outlines the changes to the clinical trial process, accelerated drug approval, fast track of rare disease products and access opportunities in China's evolving healthcare environment.Find out more here-...
Event: Richard Head presented with MR Excellence award at EphMRA Conference
Research Partnership were delighted to exhibit, sponsor and present three papers at the EphMRA conference where Director Richard Head was presented with one of this year's MR Excellence Awards.Find out...
How patient insights were brought to life with graphic novel outputs
Research Partnership's client was developing a novel therapy for the treatment of a rare disease in which patients suffer acute symptomatic attacks; the main burden of disease is not just...
Research Partnership publishes new patient Living with Ankylosing Spondylitis & nr-axSpA EU & US 2019 reports
Living with Ankylosing Spondylitis (AS) & nr-AxSpA are reports based on quantitative studies conducted online in the 5EU and US. The AS 5EU report comprises of interviews with 385 patients...